breast cancer

Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer. The results of the trial, released Monday, included estrogen...

AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study. The results showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...

The National Cancer Institute (NCI), recently awarded $3.2 million to researchers studying the effects of medical marijuana in breast cancer treatment. The University of Florida Health Center reported that scientists hypothesize that medical marijuana could improve...

Cannabis company MariMed (CSE: MRMD) (OTCQX: MRMD) will make a monetary donation to the Keep A Breast (KAB) Foundation via its Betty’s Eddies brand that will advance breast cancer awareness education and support the millions of people affected by the disease. The...

Several cannabis companies such as RISE, Ghostbudsters Farm, Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) and 4Front Ventures Corp. (OTCQX: FFNTF), have launched fundraising and awareness initiatives, in honor of Breast Cancer Awareness Month. Benzinga has learned exclusively that...

Novartis AG (NYSE: NVS) has announced updated median overall survival (OS) results for Kisqali (ribociclib) combined with fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast...

Health Canada has approved Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) setting. The approval covers Keytruda combined with chemotherapy as neoadjuvant treatment and then continued as...

AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy endpoint was met (increase in CD8⍺ in TME). A uniform increase of immune markers upon...

Celcuity Inc (NASDAQ: CELC) concluded two formal meetings with the FDA to obtain their feedback on the gedatolisib Phase 3 trial in the breast cancer setting. The study dubbed VIKTORIA-1 will evaluate gedatolisib combined with fulvestrant with or without palbociclib in HR+/HER2-...

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in the Phase 2 AMEERA-3 trial. Results from the Phase 2 trial showed that the drug amcenestrant, given as a pill, did not...

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-stage breast cancer with certain mutations. The agency approved Lynparza (olaparib) for patients with a form of...

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE: NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were...

Immutep Limited (NASDAQ: IMMP) has received constructive feedback from the FDA regarding its clinical development program for eftilagimod alpha (efti or IMP321) in metastatic breast cancer (MBC).  The agency has supported Immutep's view to continue exploring the development...

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer. The trial included breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors, and...

AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2. Data from the pivotal DESTINY-Breast04 Phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a...